CS12-05 The Management of Chronic Hepatitis B Virus Infection in Immunosuppressed Patients  by Wang, Gui-Qiang
Concurrent Sessions S17
HBsAg-negative donors sometimes contained HBV DNA. With im-
provements in HBV DNA ampliﬁcation technology, we are now
approaching single genome detection capabilities. When coupled
with enhancements in the sensitivity and speciﬁcity of assays
for anti-HBc and HBsAg, previous misinterpretations are being
revised, and we now have a better understanding of risk.
Most experts would concur that blood collected during the early
seronegative window period of HBV (when only HBV DNA is
present) is highly infectious. This risk appears to be greater
during the expansion phase of HBV DNA than that which is seen
during the recovery phase of acute disease when anti-HBs may
complex with the virus leading to modulation of the disease pro-
cess and a reduction in the risk of transmission despite detection
of HBV DNA.
Following the uneven implementation of ultrasensitive nucleic
acid testing of blood donors in various regions of the world,
the residual risk of HBV was found to be inconstant with inci-
dence/window period rates varying from 1:350,000 in the US and
Europe to 1:50,000 in Japan and to 1:5000 or lower in Southeast
Asia and Pakistan. As interest in evaluating the residual yield of
HBV DNA positive donations in HBsAg and anti-HBc negative donor
samples (seronegative window period donations) has intensiﬁed,
some unexpected ﬁndings have emerged. For example, from Jan-
uary 2008 to January 2009, the American Red Cross (ARC) tested
3,694,858 units of blood for HBV DNA either in minipools of 16
donations (84.4%) or as individual donations (16.6%) (Stramer et
al, 2009). HBV DNA was detected in 9 donors (1:410,000) with
only one of these (11%) requiring individual testing (ID-NAT) for
detection (i.e., not detected by minipool testing). Enrollment
and follow-up data were not available for 2 of the donors. Of
the 7 remaining donors in whom data were available, 5 were
in vaccinated individuals. Four of these were anti-HBs positive
in the index donation (anti-HBs concentrations from 3-43 IU/L)
whereas one became anti-HBs positive within 45 days. Viral loads
in these index donations were low and ranged from 100-200
copies/mL (∼16-33 IU/mL). Six of the 7 donors became IgM
anti-HBc positive and only one was a ﬁrst-time donor. Of interest
was the fact that 5 of the donors were subsequently discovered
to have sexual partners who were HBV chronic carriers with HBV
DNA viral loads >108 copies/mL in the 4 samples that were
available for testing. Among the 7 genotyped donor isolates, 4
represented genomes not typically found in the US (B2, C2, D3,
F1; all from vaccinated donors) while 3 were primarily of US
origin (A2). The infected partners associated with 4 of the donors
had the same subgenotype, and full genome sequences veriﬁed
the close relationship between these isolates.
Among the 5 vaccinated donors who were followed for 119-320
days, none developed ALT levels above 19 U/L or complained of
symptoms and all became HBV DNA negative, thereby conﬁrming
the effectiveness of vaccination in preventing clinical disease.
Only 3 of the 7 HBV DNA positive donors developed detectable
HBsAg. A group in Taiwan (Wang et al, 2002) observed the devel-
opment of HBV DNA in three vaccinated children within a week
after receiving blood that resulted in an aborted subclinical
infection similar to what was seen in the ARC donors. It is note-
worthy that both unvaccinated ARC donors who were followed
for at least 228 days developed signiﬁcant ALT abnormalities (119
U/L and 640 U/L).
An important issue is whether anti-HBs in conjunction with a
low viral load in a donor is sufﬁcient to prevent transmission
of HBV to a recipient. There are several studies which suggest
that this is a rare event. Mosley et al (1995) found no HBV
transmission associated with a donor whose anti-HBs values were
at least comparable to a level of 15 IU/L regardless of anti-HBc
status. Satake et al (2007) detected no infections in 22 HBV DNA
positive components that contained anti-HBs compared to 10 in-
fections that occurred among 37 components devoid of anti-HBs
(27%). Moreover, Aach et al (1974) were unable to detect any
transmission from HBV immune donors. Dreier and coworkers
(2004) and Gerlich (2006) failed to document transmission of HBV
from donors who were HBV DNA positive at levels <260 IU/mL,
but whose blood contained signiﬁcant levels of anti-HBs (>1000
IU/L). Conversely, low levels of anti-HBs (<75 IU/L) in HBV DNA
containing blood may carry a risk of transmission leading to
acute hepatitis in a recipient (Levicnik-Stezinar et al, 2008).
Fortunately, fulminant hepatitis is virtually unheard of following
posttransfusion hepatitis B.
In summary, nucleic acid testing is capable of detecting HBV
DNA in the absence of HBsAg and anti-HBc in a limited number
of donors with a yield that approaches ∼1:410,000 donors. The
issue of transmissibility from window period donations exists at
some ﬁnite level in unvaccinated donors in which the yield is
∼1:690,000. The public health beneﬁts of HBV NAT in blood banks
remain unknown but are likely to be marginal at considerable
cost in the US and Europe, but necessary in countries where the
disease is endemic.
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The immunosuppression by chemotherapy or immunosuppressive
therapy in chronic hepatitis B virus (HBV) infection is an in-
creasing risk for reactivation of hepatitis B and may lead to
acute hepatitis, chronic hepatitis, or even fulminant hepatitis
and death. Several studies have shown a signiﬁcant beneﬁt by
antiviral therapy with lamivudine to avoid reactivation, and the
prophylaxis with antiviral agents should be superior to therapy of
reactivation.
A rational approach to avoid the reactivation hepatitis B in these
patients has been developed, including (a) the evaluation of
HBV markers and liver condition in all patients before starting
immunosuppressive therapies; (b) the vaccination to patients
without detection of HBsAg or without sufﬁcient anti-HBs-titer;
(c) the treatment with antiviral agents of chronic hepatitis B
patients; (d) the prophylaxis use of antiviral agents such as
lamivudine in all HBsAg positive carriers; (d) the biochemical,
HBsAg and HBV DNA monitoring in subjects with HBsAg negative
and anti-HBc positive, or in subjects with markers of previous
contact with HBV; (e) the prophylaxis use of antiviral agents
before intense immunosuppression such as bone marrow trans-
plantation if anti-HBc positive, independent from HBsAg result.
Lamivudine has been approved to be effective and safe in
the management of immunosuppressive patients, other nucleo-
side analogues (telbivudine, entecavir) or nucleotide analogues
(adefovir dipivoxil, tenofovir) are potential candidates in this
situation, but larger experiences are yet missing.
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Resistance in Mycobacterium tuberculosis arises from man-made
selection of genetic mutants that result from spontaneous chro-
mosomal alterations. Thus, drug-resistant tuberculosis (TB) is
generally due to inappropriate treatment regimen, poor drug
quality, erratic drug supply and poor patient adherence to treat-
ment, reﬂecting failure in the implementation of an effective
TB control programme. Multidrug-resistant TB (MDR-TB) usually
denotes bacillary resistance to at least isoniazid and rifampicin
in vitro. Directly observed treatment, short-course (DOTS) is a
cost-effective strategy for TB control. Proper implementation of
the DOTS strategy should achieve a high cure rate for disease
